CIS BIO INTL
BiotechCIS BIO INTL is a biotechnology company focused on Respiratory. Key products include PULMOTECH MAA.
Upcoming FDA Decisions
Full Calendar →CIS BIO INTL's Key Drugs
CIS BIO INTL's core commercial portfolio centers on PULMOTECH MAA, spanning Respiratory — its most strategically important drugs approved in the last 15 years.
CIS BIO INTL's Recent FDA Approvals
New NDA/BLA approvals for CIS BIO INTL over the last two years — novel drugs only, excluding generics and label supplements.
CIS BIO INTL's Therapeutic Areas
CIS BIO INTL's approved drugs and pipeline span 1 therapeutic area, led by Respiratory, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CIS BIO INTL's Top Competitors
CIS BIO INTL's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and GSK. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CIS BIO INTL Pipeline Snapshot
Active clinical trials for CIS BIO INTL across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • PULMOTECH MAA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Respiratory pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2020-03-20
- Latest
- 2023-08-25
- Applications
- 1